Anti–programmed cell death ligand 1 therapy could make tumor susceptible to anti-angiogenic therapy and prolong its efficacy, and conversely, anti-angiogenic therapy could improve anti-programmed cell death ligand 1 treatment specifically when it generates intratumoral high endothelial venules that facilitate enhanced cytotoxic T cells infiltration, activity, and cancer cells destruction [72]. The gene discussed is CD274; the disease is neoplasm.